Loteprednol Etabonate
Loteprednol Etabonate is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Loteprednol Etabonate; Generic name: LOTEPREDNOL ETABONATE; Manufacturer: ARMAS PHARMACEUTICALS INC..
| Brand name | Loteprednol Etabonate |
|---|---|
| Generic name | LOTEPREDNOL ETABONATE |
| Manufacturer | ARMAS PHARMACEUTICALS INC. |
| Used for | INDICATIONS AND USAGE Loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. Loteprednol etabonate is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate experienced resolution of ante |
| Dosage | DOSAGE AND ADMINISTRATION SHAKE VIGOROUSLY BEFORE USING. Steroid Responsive Disease Treatment: Apply one to two drops of loteprednol etabonate into the conjunctival sac of the affected eye four times daily. During the initial treatment within the first week, the dosing may be increased, up to 1 drop every hour, if necessary. Care should be taken not to discontinue therapy prematurely. If signs and symptoms fail to improve after two days, the patient should be re-evaluated (See PRECAUTIONS ). Pos |
| Warnings | WARNINGS Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision, and in posterior subcapsular cataract formation. Steroids should be used with caution in the presence of glaucoma. Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of to |
| Active ingredient(s) | LOTEPREDNOL ETABONATE |
| Route | OPHTHALMIC |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=08a091a8-748f-acc4-e063-6394a90af4bc |